7 completed, 2 terminated. 9 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 7, Terminated 2 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
Follow Trypanosomiasis, African: new trials by email Literature Review of Trypanosomiasis, African trials Research Report on Trypanosomiasis, African
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients Acoziborole - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 35 | 2022-07-09 | 2026-04-06 |
| Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects Acoziborole, Placebo - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 1208 | 2021-12-30 | 2025-03-20 |
| Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense Fexinidazole - Trypanosomiasis, African, Sleeping Sickness | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 45 | 2019-09-29 | 2025-01-30 |
| Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Fexinidazole - Trypanosomiasis, African, Sleeping Sickness | Phase 3 | Completed | Drugs for Neglected Diseases | 174 | 2016-11-10 | 2025-01-08 |
| Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense Acoziborole - Trypanosomiasis, African, Gambiense Trypanosomiasis | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 208 | 2016-10-11 | 2025-09-17 |
| Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Fexinidazole, Nifurtimox, Eflornithine - Human African Trypanosomiasis (HAT), Sleeping Sickness | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 394 | 2012-10-01 | 2018-02-20 |
| Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Eflornithine plus Nifurtimox combination therapy - Trypanosomiasis, African | Phase 2 / Phase 3 | Terminated | Epicentre | 31 | 2002-10-01 | 2007-06-21 |
| Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d, melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d, nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d - Trypanosomiasis, African | Phase 3 | Terminated | Epicentre | 435 | 2001-03-01 | 2006-05-26 |
| Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Eflornithine, Nifurtimox - Trypanosomiasis, African | Phase 3 | Completed | Drugs for Neglected Diseases | 280 | 2016-09-29 |
Infections (3) · Trypanosomiasis (2) · Neglected Diseases (1)
Euglenozoa Infections (9) · Parasitic Diseases (9) · Protozoan Infections (9) · Vector Borne Diseases (9) · Trypanosomiasis (7) · Infections (6) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Eflornithine (4) · Nifurtimox (3) · fexinidazole (3) · Melarsoprol (1) · SCYX 7158 (1)
Drugs for Neglected Diseases (7) · Epicentre (2)
Democratic Republic of the Congo (6) · Guinea (4) · Uganda (3) · Republic of the Congo (2) · Central African Republic (1) · Malawi (1)
Gerardo Priotto, MD, MPH (2) · Digas Ngolo Tete, MPH (1) · Els Torreele, PhD (1) · Enock Matovu, Prof (1) · Gerardo Priotto, MD MPH (1) · Mamadou Camara, PhD (1) · Patrice Piola, MD MSc (1) · Victor Kande Betu Kumeso, Dr (1) · Victor Kande Betu Kumeso, Dr. (1) · Victor Kande Betu Kumeso, MD (1)
PMID 19559476, PMID 29113731, PMID 36460027, PMID 40288399, PMID 40288400